Mimedx (MDXG) Capital Expenditures Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.73% |
| Dec 31, 2025 | -33.28% |
| Sep 30, 2025 | -21.69% |
| Jun 30, 2025 | -15.27% |
| Mar 31, 2025 | -17.90% |
| Dec 31, 2024 | -17.71% |
| Sep 30, 2024 | 1.85% |
| Jun 30, 2024 | -16.00% |
| Mar 31, 2024 | 12.04% |
| Dec 31, 2023 | 1.67% |
| Sep 30, 2023 | -19.68% |
| Jun 30, 2023 | -34.46% |
| Mar 31, 2023 | -27.07% |
| Dec 31, 2022 | -9.97% |
| Sep 30, 2022 | -38.55% |
| Jun 30, 2022 | 137.77% |
| Mar 31, 2022 | 63.82% |
| Dec 31, 2021 | 15.58% |
| Sep 30, 2021 | -18.76% |
| Jun 30, 2021 | -25.35% |
| Mar 31, 2021 | -0.68% |
| Dec 31, 2020 | 5.47% |
| Sep 30, 2020 | -17.08% |
| Jun 30, 2020 | -18.86% |
| Mar 31, 2020 | -5.58% |
| Dec 31, 2019 | -22.35% |
| Sep 30, 2019 | 42.02% |
| Jun 30, 2019 | 53.98% |
| Mar 31, 2019 | 81.39% |
| Dec 31, 2018 | 24.05% |
| Sep 30, 2018 | 16.48% |
| Jun 30, 2018 | 20.34% |
| Mar 31, 2018 | 110.91% |
| Dec 31, 2017 | 36.84% |
| Sep 30, 2017 | 89.41% |
| Jun 30, 2017 | -53.84% |
| Dec 31, 2016 | -66.24% |
| Sep 30, 2016 | 66.46% |
| Jun 30, 2016 | 123.25% |
| Mar 31, 2016 | 78.14% |